Published in Haematologica on February 01, 2008
Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol (2011) 2.82
Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc (2011) 1.53
Predictors of survival to orthotopic heart transplant in patients with light chain amyloidosis. J Heart Lung Transplant (2013) 1.50
Al amyloidosis. Orphanet J Rare Dis (2012) 1.29
Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. Am J Hematol (2011) 1.17
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood (2012) 1.08
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients. Leukemia (2014) 1.06
Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). Haematologica (2014) 1.04
Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia. Leuk Lymphoma (2009) 1.00
A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis. Leukemia (2014) 0.99
Current treatment of AL amyloidosis. Haematologica (2009) 0.95
Systemic amyloidosis: a challenge for the rheumatologist. Nat Rev Rheumatol (2010) 0.94
Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies. Clin Biochem Rev (2009) 0.87
Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood (2012) 0.86
Splenic plasma cells can serve as a source of amyloidogenic light chains. Blood (2008) 0.84
The amyloidoses: clinical features, diagnosis and treatment. Methodist Debakey Cardiovasc J (2012) 0.82
Amyloidosis and POEMS syndrome. Expert Opin Pharmacother (2010) 0.81
Successful management of refractory pleural effusion due to systemic immunoglobulin light chain amyloidosis by vincristine adriamycin dexamethasone chemotherapy: a case report. J Med Case Rep (2010) 0.80
Autologous stem cell transplant for Al amyloidosis. Bone Marrow Res (2012) 0.80
Effectiveness of bortezomib in cardiac Al amyloidosis: a report of two cases. Case Rep Med (2014) 0.78
Amyloidosis relapsing after autologous stem cell transplantation treated with bortezomib: normalization of detectable serum-free light chains and reversal of tissue damage with improved suitability for transplant. Haematologica (2009) 0.77
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. Blood (2014) 0.77
Bortezomib in the management of multiple myeloma. Cancer Manag Res (2009) 0.77
The Clinical Presentation and Management of Systemic Light-Chain Amyloidosis in China. Kidney Dis (Basel) (2016) 0.75
NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity (2004) 13.55
Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum (2004) 7.07
Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med (2006) 6.17
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol (2005) 5.64
Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med (2009) 5.19
Natural history and outcome in systemic AA amyloidosis. N Engl J Med (2007) 4.54
Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med (2002) 4.47
T1 mapping for myocardial extracellular volume measurement by CMR: bolus only versus primed infusion technique. JACC Cardiovasc Imaging (2013) 4.21
Targeting C-reactive protein for the treatment of cardiovascular disease. Nature (2006) 4.07
Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med (2013) 3.97
Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med (2003) 3.86
Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging (2013) 3.53
Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med (2007) 3.38
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol (2012) 3.35
Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol (2007) 3.12
Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol (2003) 2.74
Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum (2002) 2.58
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood (2013) 2.38
In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med (2009) 2.34
Infusion of pharmaceutical-grade natural human C-reactive protein is not proinflammatory in healthy adult human volunteers. Circ Res (2013) 2.26
Updates in cardiac amyloidosis: a review. J Am Heart Assoc (2012) 2.21
Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol (2010) 2.20
Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum (2002) 2.19
Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson (2008) 2.01
Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ Res (2005) 1.91
Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. N Engl J Med (2015) 1.84
Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature (2010) 1.81
Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood (2012) 1.80
Abnormal tumor necrosis factor receptor I cell surface expression and NF-kappaB activation in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum (2008) 1.61
Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. Heart (2012) 1.56
Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood (2006) 1.54
Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum (2003) 1.51
Familial Mediterranean fever caused by homozygous E148Q mutation complicated by Budd-Chiari syndrome and polyarteritis nodosa. Rheumatology (Oxford) (2010) 1.44
Inflammatory bowel disease and systemic AA amyloidosis. Dig Dis Sci (2013) 1.43
Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation. Nephrol Dial Transplant (2008) 1.37
An international registry on autoinflammatory diseases: the Eurofever experience. Ann Rheum Dis (2012) 1.36
Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Lung Transplant (2004) 1.36
Systemic amyloidosis and the gastrointestinal tract. Nat Rev Gastroenterol Hepatol (2009) 1.34
Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. Am J Med (2006) 1.32
Human plasma fibrinogen is synthesized in the liver. Blood (2006) 1.27
Hereditary systemic amyloidosis due to Asp76Asn variant β2-microglobulin. N Engl J Med (2012) 1.26
Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging (2012) 1.25
Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Hum Mutat (2014) 1.23
Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood (2005) 1.22
Outcome in renal Al amyloidosis after chemotherapy. J Clin Oncol (2011) 1.21
AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. Blood (2008) 1.20
Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc (2013) 1.20
Perspectives in treatment of AL amyloidosis. Br J Haematol (2007) 1.17
Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. Br J Haematol (2006) 1.13
Quantitative high-resolution microradiographic imaging of amyloid deposits in a novel murine model of AA amyloidosis. Amyloid (2005) 1.13
Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol (2006) 1.12
Liver transplantation in transthyretin-related familial amyloid polyneuropathy. Curr Opin Neurol (2004) 1.11
The emerging role of interleukin-1β in autoinflammatory diseases. Arthritis Rheum (2011) 1.09
Systemic amyloidosis in England: an epidemiological study. Br J Haematol (2013) 1.08
Decreasing incidence of AA amyloidosis in Spain. Eur J Clin Invest (2013) 1.08
Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis. J Am Soc Nephrol (2008) 1.07
Hereditary auto-inflammatory disorders and biologics. Springer Semin Immunopathol (2006) 1.06
Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I. Am J Pathol (2011) 1.04
Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Br J Haematol (2010) 1.04